Innovation, not easy money, is behind the Nasdaq's return to 5,000
Research and Markets: Metastatic Pancreatic Cancer Pipeline Review 2015 - Analysis of 46 Companies & 66 Drug Profiles
ADDING MULTIMEDIA REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Charting a sluggish, but bullish, S&P 500 -2-
Oxis Biotech Inc. Provides Update for P62-ZZ Multiple Myeloma Patent Application
UPDATE: U.S. markets spike from major technical support
Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...
Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.
Widening investment-grade credit spreads and rising interest rates lead to losses.